### REMARKS

#### Rejection Under 35 U.S.C. §103

Claims 48-50 are rejected as being obvious in view of Black et al. (US 116) or Dodge et al. (US 417).

This rejection is render moot by the cancellation of claims 48-50. Applicants will pursue this subject matter in a divisional application.

# Rejection Under 35 U.S.C. §112, first paragraph

Claims 51-52 are rejected as non-enabled based on the recitation of "derivatives." Applicants' disclosure clearly refers to derivatives of raloxifene. See, e.g., page 6, lines 10-19. Further, applicants' disclosure refers to EP 0 635 270 with regards to a use of raloxifene and derivatives thereof. EP'270 further cites US 4,418,068 as disclosing raloxifene. See the examples of US '068 which describe raloxifene and its hydrochloride salt.

The form of raloxifene that is commonly used is the hydrochloride salt. See, e.g., USP Dictionary of USAN and International Drug Names (2001), p. 746. The USP Dictionary indicates that "Raloxifene" is the INN name for raloxifien hydrochloride. Thus, one of ordinary skill in the art would clearly recognize that applicants' disclosure of raloxifene and derivatives thereof would encompass the hydrochloride salt. See also the disclosure of EP '270 which also describes the hydrochloride salt of raloxifene.

To further prosecution, applicants have amended claims 51 and 52 to refer to the hydrochloride salt of raloxifene. In view of the above remarks, withdrawal of the rejection under 35 USC §112, first paragraph, is respectfully requested.

Respectfully submitted,

Brion P. Heaney (Reg. No. 32,542)

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I

2200 Clarendon Boulevard, Suite 1400

Arlington, Virginia 22201 Direct Dial: (703) 812-5308 Facsimile: (703) 243-6410

Internet Address: heaney@mwzb.com

Filed: April 3, 2002 BPH:K:\Sch\1655\Reply 4-3-02.doc

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

## **IN THE CLAIMS**:

#### Please amend claims 51-52 as follows:

- --51. A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and Raloxifen or the hydrochloride salt thereof a derivative thereof wherein said one or more LHRH analogues and Raloxifen, or a derivative thereof, are administered sequentially or simultaneously.
- 52. A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of Raloxifen or the hydrochloride salt thereof a derivative thereof.--